-
1
-
-
84892805731
-
Cancer statistics, 2014
-
Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64(1):9–29.
-
(2014)
CA Cancer J Clin
, vol.64
, Issue.1
, pp. 9-29
-
-
Siegel, R.1
Ma, J.2
Zou, Z.3
Jemal, A.4
-
2
-
-
84901400296
-
Analysis of the status and trends of prostate cancer incidence in China
-
Chinese
-
Han S, Zhang S, Chen W, et al. [Analysis of the status and trends of prostate cancer incidence in China]. Chin Clin Oncol. 2013;(04):330–334. Chinese.
-
(2013)
Chin Clin Oncol
, Issue.4
, pp. 330-334
-
-
Han, S.1
Zhang, S.2
Chen, W.3
-
3
-
-
84929396356
-
Analysis of the status and trends of prostate cancer mortality in China
-
Chinese
-
Han S, Zhang S, Chen W, et al. [Analysis of the status and trends of prostate cancer mortality in China]. Chin J Urol. 2012;33(11):836–839. Chinese.
-
(2012)
Chin J Urol
, vol.33
, Issue.11
, pp. 836-839
-
-
Han, S.1
Zhang, S.2
Chen, W.3
-
4
-
-
84888815889
-
EAU guidelines on prostate cancer. Part 1: Screening, diagnosis, and local treatment with curative intent-update 2013
-
Heidenreich A, Bastian PJ, Bellmunt J, et al. EAU guidelines on prostate cancer. part 1: Screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol. 2014;65(1):124–137.
-
(2014)
Eur Urol
, vol.65
, Issue.1
, pp. 124-137
-
-
Heidenreich, A.1
Bastian, P.J.2
Bellmunt, J.3
-
5
-
-
84857774190
-
Molecular pathways: Beta-adrenergic signaling in cancer
-
Cole SW, Sood AK. Molecular pathways: Beta-adrenergic signaling in cancer. Clin Cancer Res. 2012;18(5):1201–1206.
-
(2012)
Clin Cancer Res
, vol.18
, Issue.5
, pp. 1201-1206
-
-
Cole, S.W.1
Sood, A.K.2
-
6
-
-
77956931932
-
The sympathetic nervous system induces a metastatic switch in primary breast cancer
-
Sloan EK, Priceman SJ, Cox BF, et al. The sympathetic nervous system induces a metastatic switch in primary breast cancer. Cancer Res. 2010;70(18):7042–7052.
-
(2010)
Cancer Res
, vol.70
, Issue.18
, pp. 7042-7052
-
-
Sloan, E.K.1
Priceman, S.J.2
Cox, B.F.3
-
7
-
-
84864418995
-
Stimulation of host bone marrow stromal cells by sympathetic nerves promotes breast cancer bone metastasis in mice
-
Campbell JP, Karolak MR, Ma Y, et al. Stimulation of host bone marrow stromal cells by sympathetic nerves promotes breast cancer bone metastasis in mice. PLoS Biol. 2012;10(7):e1001363.
-
(2012)
Plos Biol
, vol.10
, Issue.7
-
-
Campbell, J.P.1
Karolak, M.R.2
Ma, Y.3
-
8
-
-
33746851955
-
Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma
-
Thaker PH, Han LY, Kamat AA, et al. Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nat Med. 2006;12(8):939–944.
-
(2006)
Nat Med
, vol.12
, Issue.8
, pp. 939-944
-
-
Thaker, P.H.1
Han, L.Y.2
Kamat, A.A.3
-
9
-
-
33646371479
-
The norepinephrine-driven metastasis development of PC-3 human prostate cancer cells in BALB/c nude mice is inhibited by beta-blockers
-
Palm D, Lang K, Niggemann B, et al. The norepinephrine-driven metastasis development of PC-3 human prostate cancer cells in BALB/c nude mice is inhibited by beta-blockers. Int J Cancer. 2006;118(11):2744–2749.
-
(2006)
Int J Cancer
, vol.118
, Issue.11
, pp. 2744-2749
-
-
Palm, D.1
Lang, K.2
Niggemann, B.3
-
10
-
-
84879685044
-
Beta-blockers increase response to chemotherapy via direct antitumour and anti-angiogenic mechanisms in neuroblastoma
-
Pasquier E, Street J, Pouchy C, et al. Beta-blockers increase response to chemotherapy via direct antitumour and anti-angiogenic mechanisms in neuroblastoma. Br J Cancer. 2013;108(12):2485–2494.
-
(2013)
Br J Cancer
, vol.108
, Issue.12
, pp. 2485-2494
-
-
Pasquier, E.1
Street, J.2
Pouchy, C.3
-
11
-
-
84893854541
-
Anti-tumor activity of the beta-adrenergic receptor antagonist propranolol in neuroblastoma
-
Wolter JK, Wolter NE, Blanch A, et al. Anti-tumor activity of the beta-adrenergic receptor antagonist propranolol in neuroblastoma. Oncotarget. 2014;5(1):161–172.
-
(2014)
Oncotarget
, vol.5
, Issue.1
, pp. 161-172
-
-
Wolter, J.K.1
Wolter, N.E.2
Blanch, A.3
-
12
-
-
84858428443
-
Propranolol potentiates the anti-angiogenic effects and anti-tumor efficacy of chemotherapy agents: Implication in breast cancer treatment
-
Pasquier E, Ciccolini J, Carre M, et al. Propranolol potentiates the anti-angiogenic effects and anti-tumor efficacy of chemotherapy agents: Implication in breast cancer treatment. Oncotarget. 2011;2(10):797–809.
-
(2011)
Oncotarget
, vol.2
, Issue.10
, pp. 797-809
-
-
Pasquier, E.1
Ciccolini, J.2
Carre, M.3
-
13
-
-
84898702870
-
Therapeutic effect of beta-blockers in triple-negative breast cancer postmenopausal women
-
Botteri E, Munzone E, Rotmensz N, et al. Therapeutic effect of beta-blockers in triple-negative breast cancer postmenopausal women. Breast Cancer Res Treat. 2013;140(3):567–575.
-
(2013)
Breast Cancer Res Treat
, vol.140
, Issue.3
, pp. 567-575
-
-
Botteri, E.1
Munzone, E.2
Rotmensz, N.3
-
14
-
-
84888876235
-
Effect of beta-blockers and other antihypertensive drugs on the risk of melanoma recurrence and death
-
De Giorgi V, Gandini S, Grazzini M, Benemei S, Marchionni N, Geppetti P. Effect of beta-blockers and other antihypertensive drugs on the risk of melanoma recurrence and death. Mayo Clin Proc. 2013;88(11):1196–1203.
-
(2013)
Mayo Clin Proc
, vol.88
, Issue.11
, pp. 1196-1203
-
-
De Giorgi, V.1
Gandini, S.2
Grazzini, M.3
Benemei, S.4
Marchionni, N.5
Geppetti, P.6
-
15
-
-
84877125671
-
Improved survival outcomes with the incidental use of beta-blockers among patients with non-small-cell lung cancer treated with definitive radiation therapy
-
Wang HM, Liao ZX, Komaki R, et al. Improved survival outcomes with the incidental use of beta-blockers among patients with non-small-cell lung cancer treated with definitive radiation therapy. Ann Oncol. 2013;24(5):1312–1319.
-
(2013)
Ann Oncol
, vol.24
, Issue.5
, pp. 1312-1319
-
-
Wang, H.M.1
Liao, Z.X.2
Komaki, R.3
-
16
-
-
84898049404
-
Stage-specific associations between beta blocker use and prognosis after colorectal cancer
-
Jansen L, Hoffmeister M, Arndt V, Chang-Claude J, Brenner H. Stage-specific associations between beta blocker use and prognosis after colorectal cancer. Cancer. 2014;120(8):1178–1186.
-
(2014)
Cancer
, vol.120
, Issue.8
, pp. 1178-1186
-
-
Jansen, L.1
Hoffmeister, M.2
Arndt, V.3
Chang-Claude, J.4
Brenner, H.5
-
17
-
-
79958717592
-
Does beta-adrenoceptor blocker therapy improve cancer survival? Findings from a population-based retrospective cohort study
-
Shah SM, Carey IM, Owen CG, Harris T, Dewilde S, Cook DG. Does beta-adrenoceptor blocker therapy improve cancer survival? Findings from a population-based retrospective cohort study. Br J Clin Pharmacol. 2011;72(1):157–161.
-
(2011)
Br J Clin Pharmacol
, vol.72
, Issue.1
, pp. 157-161
-
-
Shah, S.M.1
Carey, I.M.2
Owen, C.G.3
Harris, T.4
Dewilde, S.5
Cook, D.G.6
-
18
-
-
84872800402
-
Use of beta-blockers is associated with prostate cancer-specific survival in prostate cancer patients on androgen deprivation therapy
-
Grytli HH, Fagerland MW, Fossa SD, Tasken KA, Haheim LL. Use of beta-blockers is associated with prostate cancer-specific survival in prostate cancer patients on androgen deprivation therapy. Prostate. 2013;73(3):250–260.
-
(2013)
Prostate
, vol.73
, Issue.3
, pp. 250-260
-
-
Grytli, H.H.1
Fagerland, M.W.2
Fossa, S.D.3
Tasken, K.A.4
Haheim, L.L.5
-
19
-
-
84900521936
-
Beta-blocker usage and prostate cancer survival: A nested case-control study in the UK Clinical Practice Research Datalink cohort
-
Cardwell CR, Coleman HG, Murray LJ, O’Sullivan JM, Powe DG. Beta-blocker usage and prostate cancer survival: A nested case-control study in the UK Clinical Practice Research Datalink cohort. Cancer Epidemiol. 2014;38(3):279–285.
-
(2014)
Cancer Epidemiol
, vol.38
, Issue.3
, pp. 279-285
-
-
Cardwell, C.R.1
Coleman, H.G.2
Murray, L.J.3
O’Sullivan, J.M.4
Powe, D.G.5
-
20
-
-
84895064442
-
Association between use of beta-blockers and prostate cancer-specific survival: A cohort study of 3,561 prostate cancer patients with high-risk or metastatic disease
-
Grytli HH, Fagerland MW, Fossa SD, Tasken KA. Association between use of beta-blockers and prostate cancer-specific survival: A cohort study of 3,561 prostate cancer patients with high-risk or metastatic disease. Eur Urol. 2014;65(3):635–641.
-
(2014)
Eur Urol
, vol.65
, Issue.3
, pp. 635-641
-
-
Grytli, H.H.1
Fagerland, M.W.2
Fossa, S.D.3
Tasken, K.A.4
-
21
-
-
0034685429
-
Meta-analysis of observational studies in epidemiology: A proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group
-
Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: A proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000;283(15):2008–2012.
-
(2000)
JAMA
, vol.283
, Issue.15
, pp. 2008-2012
-
-
Stroup, D.F.1
Berlin, J.A.2
Morton, S.C.3
-
22
-
-
0022992740
-
Meta-analysis in clinical trials
-
DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177–188.
-
(1986)
Control Clin Trials
, vol.7
, Issue.3
, pp. 177-188
-
-
Dersimonian, R.1
Laird, N.2
-
23
-
-
0037098199
-
Quantifying heterogeneity in a meta-analysis
-
Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539–1558.
-
(2002)
Stat Med
, vol.21
, Issue.11
, pp. 1539-1558
-
-
Higgins, J.P.1
Thompson, S.G.2
-
24
-
-
84925456716
-
Post-diagnostic use of beta-blockers and the risk of death in patients with prostate cancer
-
Assayag J, Pollak MN, Azoulay L. Post-diagnostic use of beta-blockers and the risk of death in patients with prostate cancer. Eur J Cancer. 2014;50(16):2838–2845.
-
(2014)
Eur J Cancer
, vol.50
, Issue.16
, pp. 2838-2845
-
-
Assayag, J.1
Pollak, M.N.2
Azoulay, L.3
-
25
-
-
10744220803
-
Stress-related mediators stimulate vascular endothelial growth factor secretion by two ovarian cancer cell lines
-
Lutgendorf SK, Cole S, Costanzo E, et al. Stress-related mediators stimulate vascular endothelial growth factor secretion by two ovarian cancer cell lines. Clin Cancer Res. 2003;9(12):4514–4521.
-
(2003)
Clin Cancer Res
, vol.9
, Issue.12
, pp. 4514-4521
-
-
Lutgendorf, S.K.1
Cole, S.2
Costanzo, E.3
-
26
-
-
46149121727
-
Perioperative use of beta-blockers and COX-2 inhibitors may improve immune competence and reduce the risk of tumor metastasis
-
Benish M, Bartal I, Goldfarb Y, et al. Perioperative use of beta-blockers and COX-2 inhibitors may improve immune competence and reduce the risk of tumor metastasis. Ann Surg Oncol. 2008;15(7):2042–2052.
-
(2008)
Ann Surg Oncol
, vol.15
, Issue.7
, pp. 2042-2052
-
-
Benish, M.1
Bartal, I.2
Goldfarb, Y.3
-
27
-
-
84904113538
-
Chronic stress accelerates pancreatic cancer growth and invasion: A critical role for beta-adrenergic signaling in the pancreatic microenvironment
-
Kim-Fuchs C, Le CP, Pimentel MA, et al. Chronic stress accelerates pancreatic cancer growth and invasion: A critical role for beta-adrenergic signaling in the pancreatic microenvironment. Brain Behav Immun. 2014;40:40–47.
-
(2014)
Brain Behav Immun
, vol.40
, pp. 40-47
-
-
Kim-Fuchs, C.1
Le, C.P.2
Pimentel, M.A.3
-
28
-
-
84873358810
-
Behavioral stress accelerates prostate cancer development in mice
-
Hassan S, Karpova Y, Baiz D, et al. Behavioral stress accelerates prostate cancer development in mice. J Clin Invest. 2013;123(2):874–886.
-
(2013)
J Clin Invest
, vol.123
, Issue.2
, pp. 874-886
-
-
Hassan, S.1
Karpova, Y.2
Baiz, D.3
-
29
-
-
4043163432
-
Antihypertensive drug use and the risk of prostate cancer (Canada)
-
Perron L, Bairati I, Harel F, Meyer F. Antihypertensive drug use and the risk of prostate cancer (Canada). Cancer Causes Control. 2004;15(6):535–541.
-
(2004)
Cancer Causes Control
, vol.15
, Issue.6
, pp. 535-541
-
-
Perron, L.1
Bairati, I.2
Harel, F.3
Meyer, F.4
-
30
-
-
82955212735
-
The association between antihypertensive drug use and incidence of prostate cancer in Finland: A population-based case-control study
-
Kemppainen KJ, Tammela TL, Auvinen A, Murtola TJ. The association between antihypertensive drug use and incidence of prostate cancer in Finland: A population-based case-control study. Cancer Causes Control. 2011;22(10):1445–1452.
-
(2011)
Cancer Causes Control
, vol.22
, Issue.10
, pp. 1445-1452
-
-
Kemppainen, K.J.1
Tammela, T.L.2
Auvinen, A.3
Murtola, T.J.4
-
31
-
-
84871180180
-
Cabazitaxel: More than a new taxane for metastatic castrate-resistant prostate cancer
-
Mita AC, Figlin R, Mita MM. Cabazitaxel: More than a new taxane for metastatic castrate-resistant prostate cancer. Clin Cancer Res. 2012;18(24):6574–6579.
-
(2012)
Clin Cancer Res
, vol.18
, Issue.24
, pp. 6574-6579
-
-
Mita, A.C.1
Figlin, R.2
Mita, M.M.3
-
32
-
-
84904658346
-
Taxanes in the management of metastatic castration-resistant prostate cancer: Efficacy and management of toxicity
-
Schutz FA, Buzaid AC, Sartor O. Taxanes in the management of metastatic castration-resistant prostate cancer: Efficacy and management of toxicity. Crit Rev Oncol Hematol. 2014;91(3):248–256.
-
(2014)
Crit Rev Oncol Hematol
, vol.91
, Issue.3
, pp. 248-256
-
-
Schutz, F.A.1
Buzaid, A.C.2
Sartor, O.3
|